StockData

NRX Pharmaceuticals vs Xenon Pharmaceuticals

NRXP and XENE side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How NRXP and XENE compare

Xenon Pharmaceuticals is the larger company, worth 35 times as much as NRX Pharmaceuticals ($3.8B against $106M).

Xenon Pharmaceuticals scores higher on the StockData Score (7 against 0 for NRX Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricNRXPXENE
Size and price
Market cap$106M$3.8B
Share price$2.45$38.78
Change, 1 year−1.6%−4.9%
Change, 5 years−96.4%41.3%
Beta (5Y)1.150.26
Employees29370
StockData Score
Total score07 (better)
Valuation score00
Growth score00
Performance score01 (better)
Health score06 (better)
Dividend score00
Valuation
P/S31.3×–
P/B–3.0×
FCF yield–−9.0%
Growth
Revenue growth (TTM)–−100%
Revenue growth, 5Y average–−25.3%
Profitability
Gross margin46.6%–
Operating margin−586%–
Net margin−692%–
Return on equity–−43.6%
Return on invested capital–−152%
Financial health
Debt / equity–0.00
Interest coverage−17.4×–
Current ratio0.8621.02 (better)
Altman Z-score−13.4540.35 (better)
Piotroski F-score5 (better)3
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions26.9%104%
Held by insiders15.6%0.17%
Insider net buying, 12 months–−$20.3M
Superinvestors holding–1
Short interest, % of float28.6%7.6%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.